Cabaletta Bio’s Post

Important read 👇🏽

PICI Center Directors Crystal Mackall, MD, and Carl June, MD, and PICI CSO John Connolly, PhD, collaborated with ISCT, International Society for Cell & Gene Therapy to address a crucial concern raised by the FDA regarding T-cell malignancy in patients treated with BCMA- or CD19-directed autologous CAR T-cell immunotherapy. “Unanswered questions following reports of secondary malignancies after CAR T-cell therapy," published in Nature Medicine, explores the complexities surrounding the potential risks while emphasizing the continued importance of CAR T-cell therapies. PICI and the consortia agree that while these reports warrant investigation, existing follow-up data suggest a relatively low risk compared to other cancer treatments. The commentary emphasizes that the continued benefits of CAR T-cell therapies outweigh the potential risks for most patients. However, vigilance, monitoring, and ongoing research for safety and efficacy are crucial. Read the full paper: https://lnkd.in/giRZ7_xz #CellTherapy #GeneTherapy #MedicalResearch #PICINetwork

Join this exciting webinar hosted by Ellegaard Göttingen Minipigs, who have invited a scientist to share his knowledge on "Heart Ventricular Progenitor Cell Therapy and Using Göttingen Minipigs for Development of Curative Cardiovascular Cell Therapies". #EllegaardBioresearch #GöttingenMinipigs #GöttingenMinipigsAcademy

Today marks an important milestone for Cartesian as we share positive topline results from our Phase 2b trial of Descartes-08 in patients with #myastheniagravis. Descartes-08 is the first mRNA cell therapy designed to treat MG. Learn more about the results and next steps as we continue our journey to treat #autoimmunediseases: https://bit.ly/3xJjvXA

Utilizing the scRNA-seq data of patients with PD, we longitudinally assessed changes in C1QB macrophages before CAR-T cell therapy, during CAR-T cell expansion, and during disease progression, and the results showed that the percentage of C1QB macrophages gradually increased during CAR-T cell therapy (4.17%, 5.96%, and 25.59%, respectively, Fig.  3a )

Biotech communications professionals often use terms like paradigm shifting, best-in-class, novel, etc. I’m guilty of it too. But the topline results presented today are more than just a subjective interpretation of data. Despite a relatively small study, the MG patients that responded to Descartes-08 did so with disease modifying results. This treatment didn’t just manage their symptoms – it altered how they were able to live.   Proud to be part of Cartesian Therapeutics, looking forward to advancing Descartes-08 for #myastheniagravis to a phase 3 trial, and seeing the future potential of our platform for #autoimmunity.

Calling all #lupus specialists & researchers: The April edition of our Literature Highlights & detailed slide decks are now available on the Lupus-Forum, featuring key advancements in lupus research and therapeutics. This month, we delve into topics such as the safety and efficacy of CD19 #CAR-T cell therapy, the role of #anifrolumab in treating #SLE, the establishment of autoantigen-specific Treg-cell-based therapy in #LN, and the latest on cardiovascular risk factors in #SLE patients: https://lnkd.in/dCk9aBNk

ImmunityBio is investigating immunotherapy and cell therapy combinations with the goal of improving outcomes for patients with refractory #NonHodgkinLymphoma. Learn more about our NHL clinical trial here: https://lnkd.in/gdYxczbc

We don’t want your blood (samples). We just want you to be able to analyze them with #scRNA-seq—without stressing about your schedule. That’s why we developed a first-of-its-kind protocol to fix whole blood for downstream single cell profiling. Check out our poster from #AACR24 to see what we learned about multiple myeloma by analyzing fixed blood from patients treated with #CART cell therapy: https://bit.ly/4aiko6H

In general, #oncology clinical trials — and cell therapy trials in particular — are complex undertakings that present significant regulatory, operational and patient recruitment challenges to drug developers. And for the patients who participate in these trials, the therapies under investigation could perhaps be a last hope. With potentially life-saving therapies at stake, time is of the essence. Learn more from this new white paper, which outlines operational strategies that can accelerate timelines, mitigate risks, reduce patient burden and achieve success with complex protocols, more safely and efficiently. » https://bit.ly/3WAcKQg #oncologyclinicalresearch #clinicaltrials #celltherapy #drugdevelopers